FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4367601287> ?p ?o ?g. }

• W4367601287 endingPage "OF14" @default.
• W4367601287 startingPage "OF1" @default.
• W4367601287 abstract "Abstract Purpose: Checkpoint inhibitors have limited efficacy for children with unselected solid and brain tumors. We report the first prospective pediatric trial (NCT02992964) using nivolumab exclusively for refractory nonhematologic cancers harboring tumor mutation burden (TMB) ≥5 mutations/megabase (mut/Mb) and/or mismatch repair deficiency (MMRD). Patients and Methods: Twenty patients were screened, and 10 were ultimately included in the response cohort of whom nine had TMB &gt;10 mut/Mb (three initially eligible based on MMRD) and one patient had TMB between 5 and 10 mut/Mb. Results: Delayed immune responses contributed to best overall response of 50%, improving on initial objective responses (20%) and leading to 2-year overall survival (OS) of 50% [95% confidence interval (CI), 27–93]. Four children, including three with refractory malignant gliomas are in complete remission at a median follow-up of 37 months (range, 32.4–60), culminating in 2-year OS of 43% (95% CI, 18.2–100). Biomarker analyses confirmed benefit in children with germline MMRD, microsatellite instability, higher activated and lower regulatory circulating T cells. Stochastic mutation accumulation driven by underlying germline MMRD impacted the tumor microenvironment, contributing to delayed responses. No benefit was observed in the single patient with an MMR-proficient tumor and TMB 7.4 mut/Mb. Conclusions: Nivolumab resulted in durable responses and prolonged survival for the first time in a pediatric trial of refractory hypermutated cancers including malignant gliomas. Novel biomarkers identified here need to be translated rapidly to clinical care to identify children who can benefit from checkpoint inhibitors, including upfront management of cancer." @default.
• W4367601287 created "2023-05-02" @default.
• W4367601287 creator A5001161042 @default.
• W4367601287 creator A5001392592 @default.
• W4367601287 creator A5001673025 @default.
• W4367601287 creator A5002431674 @default.
• W4367601287 creator A5010939758 @default.
• W4367601287 creator A5013395863 @default.
• W4367601287 creator A5017342460 @default.
• W4367601287 creator A5022274718 @default.
• W4367601287 creator A5028980058 @default.
• W4367601287 creator A5030969029 @default.
• W4367601287 creator A5031033801 @default.
• W4367601287 creator A5032075563 @default.
• W4367601287 creator A5033692158 @default.
• W4367601287 creator A5038007660 @default.
• W4367601287 creator A5044218928 @default.
• W4367601287 creator A5046351275 @default.
• W4367601287 creator A5052145351 @default.
• W4367601287 creator A5052728382 @default.
• W4367601287 creator A5054712515 @default.
• W4367601287 creator A5059269761 @default.
• W4367601287 creator A5060222946 @default.
• W4367601287 creator A5068257880 @default.
• W4367601287 creator A5068881416 @default.
• W4367601287 creator A5072207500 @default.
• W4367601287 creator A5077515719 @default.
• W4367601287 creator A5079323221 @default.
• W4367601287 creator A5086771704 @default.
• W4367601287 creator A5091889591 @default.
• W4367601287 date "2023-06-02" @default.
• W4367601287 modified "2023-10-18" @default.
• W4367601287 title "Efficacy of Nivolumab in Pediatric Cancers with High Mutation Burden and Mismatch Repair Deficiency" @default.
• W4367601287 doi "https://doi.org/10.1158/1078-0432.ccr-23-0411" @default.
• W4367601287 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37126021" @default.
• W4367601287 hasPublicationYear "2023" @default.
• W4367601287 type Work @default.
• W4367601287 citedByCount "1" @default.
• W4367601287 crossrefType "journal-article" @default.
• W4367601287 hasAuthorship W4367601287A5001161042 @default.
• W4367601287 hasAuthorship W4367601287A5001392592 @default.
• W4367601287 hasAuthorship W4367601287A5001673025 @default.
• W4367601287 hasAuthorship W4367601287A5002431674 @default.
• W4367601287 hasAuthorship W4367601287A5010939758 @default.
• W4367601287 hasAuthorship W4367601287A5013395863 @default.
• W4367601287 hasAuthorship W4367601287A5017342460 @default.
• W4367601287 hasAuthorship W4367601287A5022274718 @default.
• W4367601287 hasAuthorship W4367601287A5028980058 @default.
• W4367601287 hasAuthorship W4367601287A5030969029 @default.
• W4367601287 hasAuthorship W4367601287A5031033801 @default.
• W4367601287 hasAuthorship W4367601287A5032075563 @default.
• W4367601287 hasAuthorship W4367601287A5033692158 @default.
• W4367601287 hasAuthorship W4367601287A5038007660 @default.
• W4367601287 hasAuthorship W4367601287A5044218928 @default.
• W4367601287 hasAuthorship W4367601287A5046351275 @default.
• W4367601287 hasAuthorship W4367601287A5052145351 @default.
• W4367601287 hasAuthorship W4367601287A5052728382 @default.
• W4367601287 hasAuthorship W4367601287A5054712515 @default.
• W4367601287 hasAuthorship W4367601287A5059269761 @default.
• W4367601287 hasAuthorship W4367601287A5060222946 @default.
• W4367601287 hasAuthorship W4367601287A5068257880 @default.
• W4367601287 hasAuthorship W4367601287A5068881416 @default.
• W4367601287 hasAuthorship W4367601287A5072207500 @default.
• W4367601287 hasAuthorship W4367601287A5077515719 @default.
• W4367601287 hasAuthorship W4367601287A5079323221 @default.
• W4367601287 hasAuthorship W4367601287A5086771704 @default.
• W4367601287 hasAuthorship W4367601287A5091889591 @default.
• W4367601287 hasBestOaLocation W43676012871 @default.
• W4367601287 hasConcept C104317684 @default.
• W4367601287 hasConcept C109825262 @default.
• W4367601287 hasConcept C121608353 @default.
• W4367601287 hasConcept C126322002 @default.
• W4367601287 hasConcept C13514818 @default.
• W4367601287 hasConcept C142424586 @default.
• W4367601287 hasConcept C143998085 @default.
• W4367601287 hasConcept C180754005 @default.
• W4367601287 hasConcept C188816634 @default.
• W4367601287 hasConcept C2777701055 @default.
• W4367601287 hasConcept C2779767149 @default.
• W4367601287 hasConcept C2780030458 @default.
• W4367601287 hasConcept C2781197716 @default.
• W4367601287 hasConcept C44249647 @default.
• W4367601287 hasConcept C501734568 @default.
• W4367601287 hasConcept C526805850 @default.
• W4367601287 hasConcept C54355233 @default.
• W4367601287 hasConcept C60748783 @default.
• W4367601287 hasConcept C61320498 @default.
• W4367601287 hasConcept C71924100 @default.
• W4367601287 hasConcept C72563966 @default.
• W4367601287 hasConcept C86803240 @default.
• W4367601287 hasConcept C87355193 @default.
• W4367601287 hasConceptScore W4367601287C104317684 @default.
• W4367601287 hasConceptScore W4367601287C109825262 @default.
• W4367601287 hasConceptScore W4367601287C121608353 @default.
• W4367601287 hasConceptScore W4367601287C126322002 @default.
• W4367601287 hasConceptScore W4367601287C13514818 @default.
• W4367601287 hasConceptScore W4367601287C142424586 @default.
• W4367601287 hasConceptScore W4367601287C143998085 @default.

• next